Pre- or post-exposure treatment for filovirus or arenavirus infection

Abstract

The compositions and methods of the invention described herein provide pre- or post-exposure treatments against filovirus or arenavirus infection by expressing one or more genes (e.g., two or more genes) from filoviruses or arenaviruses in a delivery vehicle (e.g., a recombinant viral vector or a liposome).

What is claimed is: 
     
         1 - 37 . (canceled) 
     
     
         38 . A method of inhibiting or treating infection by  Sudan  species of Ebola virus (SEBOV) in a subject exposed to said SEBOV, said method comprising administering to said subject no later than 72 hours after infection by said SEBOV a pharmaceutical composition comprising a recombinant viral vector that encodes at least a glycoprotein from said SEBOV, wherein the glycoprotein is heterologous to the viral vector. 
     
     
         39 . The method of  claim 38 , wherein said composition comprises between 1×10 1  and 1×10 8  pfu of said viral vector. 
     
     
         40 . The method of  claim 39 , wherein said composition comprises at least 1×10 3  pfu of said viral vector. 
     
     
         41 . The method of  claim 38 , wherein said viral vector is selected from the group consisting of an adenovirus, rhabdovirus, and poxvirus vector. 
     
     
         42 . The method of  claim 38 , wherein said viral vector is a vesicular stomatitis virus (rVSV) vector. 
     
     
         43 . The method of  claim 38 , wherein said composition inhibits infection by said SEBOV. 
     
     
         44 . The method of  claim 38 , wherein said composition alleviates at least one symptom associated with said SEBOV infection. 
     
     
         45 . The method of  claim 44 , wherein said at least one symptom is hemorrhagic fever. 
     
     
         46 . The method of  claim 38 , wherein said composition induces an immune response against said SEBOV in said subject. 
     
     
         47 . The method of  claim 38 , wherein said composition further comprises a pharmaceutically acceptable diluent, excipient, carrier. 
     
     
         48 . The method of  claim 38 , wherein said composition further comprises an adjuvant. 
     
     
         49 . The method of  claim 38 , wherein said composition is formulated for parenteral, dermal, transdermal, ocular, inhalation, buccal, sublingual, perilingual, nasal, rectal, topical, or oral administration. 
     
     
         50 . The method of  claim 38 , wherein said composition is formulated for intravenous, intraperitoneal, subcutaneous, or intramuscular administration. 
     
     
         51 . The method of  claim 38 , wherein said composition is formulated for administration by injection. 
     
     
         52 . The method of  claim 38 , wherein said composition is formulated for administration two or more times. 
     
     
         53 . The method of  claim 38 , wherein said subject is a human. 
     
     
         54 . The method of  claim 38 , wherein said composition is a vaccine.